Ontology highlight
ABSTRACT: Background
Sarcopenia, the age-related, progressive loss of skeletal muscle mass, strength, and function, is a considerable socioeconomic burden by increasing risks of falls, fractures, and frailty. Moreover, sarcopenic patients are often obese and therapeutic options are very limited.Methods
Here, we assessed the efficacy of espindolol on muscle mass in 19-month-old male Wistar Han rats (weight, 555?±?18 g), including safety issues. Rats were randomized to treatment with 3 mg/kg/day espindolol (n?=?8) or placebo (n?=?14) for 31 days.Results
Placebo-treated rats progressively lost body weight (-15.5?±?7.2 g), lean mass (-1.5?±?4.2 g), and fat mass (-15.6?±?2.7 g), while espindolol treatment increased body weight (+8.0?±?6.1 g, p?ConclusionEspindolol reversed the effects of aging/sarcopenia, particularly loss of muscle mass and increased fat mass. Thus, espindolol is an attractive candidate drug for the treatment of sarcopenia patients.
SUBMITTER: Potsch MS
PROVIDER: S-EPMC4053568 | biostudies-literature | 2014 Jun
REPOSITORIES: biostudies-literature
Pötsch Mareike S MS Tschirner Anika A Palus Sandra S von Haehling Stephan S Doehner Wolfram W Beadle John J Coats Andrew J S AJ Anker Stefan D SD Springer Jochen J
Journal of cachexia, sarcopenia and muscle 20131122 2
<h4>Background</h4>Sarcopenia, the age-related, progressive loss of skeletal muscle mass, strength, and function, is a considerable socioeconomic burden by increasing risks of falls, fractures, and frailty. Moreover, sarcopenic patients are often obese and therapeutic options are very limited.<h4>Methods</h4>Here, we assessed the efficacy of espindolol on muscle mass in 19-month-old male Wistar Han rats (weight, 555 ± 18 g), including safety issues. Rats were randomized to treatment with 3 mg/kg ...[more]